Navigation Links
Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohn's Disease
Date:8/27/2012

BOTHELL, Wash., Aug. 27, 2012 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced it has received a $3.5 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2 clinical trial of ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6), in Crohn's disease.

The milestone payment is part of the collaboration between Alder and Bristol-Myers Squibb that was formed in 2009 for the development of ALD518/BMS-945429. Under the collaboration agreement, Alder granted to Bristol-Myers Squibb worldwide exclusive rights to develop and commercialize ALD518/BMS-945429 for all potential clinical uses, with the exception of cancer treatment and cancer supportive care, which are rights retained by Alder.

"We have long believed that ALD518/BMS-945429 would have potential in a large number of disease areas, and today we are excited to see Bristol-Myers Squibb advancing into another area of tremendous unmet need, Crohn's disease," said Randall Schatzman, Ph.D., president and chief executive officer of Alder Biopharmaceuticals. "We look forward to continuing with the clinical investigation in multiple areas through this partnership, including in the ongoing Phase 2b clinical trial in rheumatoid arthritis, as well as in cancer treatment and cancer supportive care on our own."

About Alder Biopharmaceuticals

Alder BioPharmaceuticals Inc. uniquely identifies, develops and manufactures novel antibody therapeutics to alleviate human suffering in cancer, pain, cardiovascular and autoimmune and inflammatory disease areas. The company's second therapeutic program, an investigational monoclonal antibody for migraine, ALD403, inhibits a well-validated molecule shown to trigger migraine attacks, calcitonin gene-related peptide (CGRP), and is now in clinical trials. ALD518 is Alder's investigational monoclonal antibody to the pro-inflammatory cytokine IL-6. Alder is developing ALD518 in Phase
'/>"/>

SOURCE Alder BioPharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
2. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
3. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
4. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
5. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
7. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
8. GeNO LLC Receives Four Additional Patents for Inhaled Nitric Oxide Delivery
9. Patient Advocate Foundation Receives Significant Support to Aid Non-Squamous Non-Small Cell Lung Cancer Patients through the Co-Pay Relief Program
10. UTHealth Receives FDA Approval To Market New Coronary Flow Reserve Quantification Software
11. Neusoft Positron Medical Systems Receives ISO Certification and CE Mark for their Attrius PET System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ... and audio webcast to discuss financial results for the second ... July 31, 2014 at 4:30 p.m. ET. ... July 31, 2014 Time: 4:30 PM ET Listen via Internet: ... A webcast replay will be available on the ...
(Date:7/28/2014)... SAN FRANCISCO , July 28, 2014 /PRNewswire/ ... that it has received the Get With The ... quality improvement measures outlined by the American Heart ... patients. Stroke is the number four cause of ... in the United States , ...
(Date:7/28/2014)... Calif., July 28, 2014 Anthera Pharmaceuticals, Inc. (NASDAQ: ... update for the second quarter ended June 30, 2014. ... 30, 2014 was $7.3 million, compared to $8.3 million for ... is a direct result of a decrease in interest expense ... the six months ended June 30, 2014 was $15.2 million, ...
Breaking Medicine Technology:Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 2Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 4Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 5Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 6Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 7
... Mass., Aug. 26, 2011 - Vention Medical, ... announced today its acquisition of ANSAmed, Ireland,s ... including multilayer, co-extrusion and multi-lumen extrusion capabilities, ... The acquisition of ANSAmed will ...
... Md., Aug. 26, 2011 The FDA reminds consumers ... safety of their food and medical supplies for themselves ... hurricane-related rain, possible flooding and power outages. ... also reminds consumers that it is important to have ...
Cached Medicine Technology:Vention Medical Acquires ANSAmed 2FDA Hurricane Preparedness Checklist 2FDA Hurricane Preparedness Checklist 3FDA Hurricane Preparedness Checklist 4
(Date:7/28/2014)... Two beneficial variants of a gene controlling red blood ... human populations across the globe, according to a new ... studied the genomes of world populations to look for ... which stimulate fetal haemoglobin production into adulthood. Fetal haemoglobin ... patients with inherited blood disorders who are able to ...
(Date:7/28/2014)... VA (PRWEB) July 29, 2014 A ... the Social Security disability trust fund by reallocating payroll ... a new poll by The Senior Citizens League ... polled said shifting revenues from the Social Security retirement ... way to fix the disability program’s financing. “TSCL believes ...
(Date:7/28/2014)... NAPW honors Pamela A. ... as a 2014 Professional Woman of the Year. Ms. ... in community health. As the largest, most-recognized networking organization ... and profession, the National Association of Professional Women (NAPW) ... members and nearly 300 Local Chapters. , In her ...
(Date:7/28/2014)... have long known that they monopolize large amounts of ... cells are also characterized by a series of features ... ordered set. Researchers are calling this behavior "mesenchymal," and ... Meylan,s research team was able to demonstrate that the ... result from the same mechanism, at least in ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Evolve Medical Clinics ... 2014, offering its members virtual visits and dramatic operational changes ... , Some estimates state that as many as 70% of ... “Imagine not having to leave your office or home for ... blood pressure or cholesterol,” CEO and Founder Michael R. Freedman, ...
Breaking Medicine News(10 mins):Health News:Study tracks worldwide spread of beneficial blood cell gene variant 2Health News:Study tracks worldwide spread of beneficial blood cell gene variant 3Health News:The Senior Citizens League Finds No Support Among Seniors for Likely Disability Trust Fund Fix 2Health News:The Senior Citizens League Finds No Support Among Seniors for Likely Disability Trust Fund Fix 3Health News:National Association of Professional Women Announces Pamela A. Schulters, Head Nurse at Kings County Hospital Center, a 2014 Professional Woman of the Year 2Health News:Cancer: Tumors absorb sugar for mobility 2Health News:Evolve Medical Clinics to Open First Next Generation Primary and Urgent Care Facility 2Health News:Evolve Medical Clinics to Open First Next Generation Primary and Urgent Care Facility 3Health News:Evolve Medical Clinics to Open First Next Generation Primary and Urgent Care Facility 4
... a precarious time, as about 15 percent of women ... risk increases when pregnant women undergo surgery, which is ... instituted a same-day pregnancy testing protocol. A study published ... shows that this protocol is effective in identifying ...
... Will Expand Product Line and International ... ... PSS Systems, the leader,in legal holds and retention management solutions, announced ... existing,investors, including Lightspeed Venture Partners, Azure Capital, Granite,Ventures, and Cipio Partners, ...
... higher rate of impairment among diabetics , , MONDAY, June ... common, under-recognized complication of diabetes, suggests a U.S. study. ... common in people with diabetes than people without the ... to be caused by other factors such as exposure ...
... emotional and,energetic performances, Garth Brooks, Jon McLaughlin, and ... Foundation, a world leader in,promoting hearing health awareness, ... World May Hear" Awards Gala, held Saturday, June ... money raised at the Gala, the Starkey,Hearing Foundation ...
... Metropolitan Health Plan (MHP(R)),the HMO of Hennepin County, ... Chief Financial Officer and David R. Johnson,Executive Director., ... County for over 35,years. During his tenure at MHP, ... Medical Assistance, to a plan that offers 10 government,sponsored ...
... - Two years ago researchers at the University of ... TDP-43 accumulated in the motor areas of the brains ... Gehrig,s disease. Now, the same group has shown that ... neurological effects than previously appreciated and treatments need to ...
Cached Medicine News:Health News:Same-day pregnancy test provides valuable guidance to pre-surgery patients 2Health News:PSS Systems Secures $18 Million in Financing 2Health News:PSS Systems Secures $18 Million in Financing 3Health News:PSS Systems Secures $18 Million in Financing 4Health News:Diabetes Might Help Spur Hearing Loss 2Health News:Garth Brooks, Jon McLaughlin, and Pat Benatar and Neil Giraldo Raise Their Voices to Help Starkey Hearing Foundation Raise More Than $5 Million at Annual Fundraiser 2Health News:Metropolitan Health Plan Announces Senior Management Appointments 2Health News:Lou Gehrig's protein found throughout brain, suggesting effects beyond motor neurons 2
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
... Tip Guidewire has a flexible, radiopaque ... tip. The longitudinal distal/proximal movement of ... proximal end of the guidewire, deflects ... Guidewire length, diameter, and distal tip ...
The 3-chip MediLive Trio Eye video camera is built to adapt to changing conditions during ophthalmic surgery with features designed for workflow optimization and maximum image quality....
... GPA software accurately differentiates clinically significant ... random variability, providing an advanced, proven ... for your patients. , ,The software ... clinical trial, in which the actual ...
Medicine Products: